drugset / Trial / NCT00006055
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Treatment
Summary
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients. III. Determine whether this treatment regimen beneficially influences the clinical course of these patients.
Timeline
- Start
- 2000-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Cyclosporine | Peptide | — | — |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |
Indications
Takayasu arteritis
autoimmune hemolytic anemia
autoimmune thrombocytopenic purpura
eosinophilic granulomatosis with polyangiitis
graft versus host disease
immunoglobulin A vasculitis
juvenile idiopathic arthritis
polyarteritis nodosa
pure red-cell aplasia
rheumatoid arthritis
systemic lupus erythematosus
temporal arteritis